Measures taken to Strengthen HPV Vaccination Programme

1. At a Glance

• Human Papillomavirus (HPV) vaccination is India's flagship intervention to eliminate cervical cancer, the second-most common cancer among Indian women [S2][S5].
• In February 2026, the Centre rolled out a nationwide HPV vaccination campaign for 14-year-old girls using Gardasil-4 in a single-dose schedule, free of cost at government facilities [S1][S2].
• Significant for UPSC as it intersects GS-II (Health Policy), GS-III (S&T, Public Health) and the 72nd Department-Related Parliamentary Standing Committee Report on HPV vaccine trials [S1].

2. Why in the News

• 13 March 2026: Ministry of Health & Family Welfare (MoHFW) released measures undertaken pursuant to the 72nd Report of the Department-Related Parliamentary Standing Committee on Health and Family Welfare on HPV vaccine trials [S1].
• 28 February 2026: PM launched the nationwide HPV vaccination drive from Ajmer, Rajasthan [S2][S3].
• Reforms cover clinical research governance, ethics oversight, AEFI safety monitoring, and integration with the U-WIN digital platform [S1].

3. Background & Evolution

• 2009: HPV demonstration project in Andhra Pradesh & Gujarat (PATH study) halted after adverse-event controversy; basis for the original Parliamentary Standing Committee scrutiny [S1].
• 2022: India's indigenous quadrivalent vaccine CERVAVAC (Serum Institute of India, backed by DBT-BIRAC) received DCGI approval [S5].
• 2024 Interim Budget: FM announced HPV vaccination for girls aged 9–14 yrs to prevent cervical cancer (Nari Shakti theme) [S5].
• Feb 2026: National rollout for 14-year-olds launched from Ajmer [S2].

4. Core Static Facts

• Implementing Ministry: Ministry of Health and Family Welfare (MoHFW) [S1].
• Vaccine deployed: Gardasil-4 (Quadrivalent) — covers HPV types 6, 11, 16, 18 [S2][S4].
• Schedule: Single dose, aligned with WHO SAGE recommendation [S2][S4].
• Target cohort: girls who have completed 14 yrs but not 15 yrs; ~1.15 crore girls/year [S2][S4].
• Digital backbone: U-WIN platform (extension of Co-WIN/eVIN) for registration & status update [S1][S2].
• Consent: Voluntary with mandatory parental consent [S1].
• Safety: AEFI (Adverse Events Following Immunization) monitoring mandated [S1].
• Parliamentary scrutiny: 72nd Report, Department-Related Standing Committee on Health & Family Welfare [S1].
• Global context: India joins 160+ countries with HPV in national immunisation [S4].

5. Multi-Dimensional Analysis

Social / Gender - Targets adolescent girls before sexual debut; addresses gender-skewed cancer burden — cervical cancer is ~1 in 5 global cases in India [S5]. - Free-at-public-facility delivery reduces out-of-pocket barrier for poor households [S2].

Scientific / Technological - Single-dose efficacy supported by WHO SAGE 2022 and Indian modelling studies [S2][S4]. - CERVAVAC marks indigenous biotech capacity (DBT-BIRAC partnership) [S5].

Ethical / Governance - Reforms triggered by 72nd PSC Report addressing informed consent failures of the 2009 PATH demonstration [S1]. - Mandatory parental consent + AEFI surveillance institutionalises ethics oversight [S1]. - Stronger clinical research and ethics framework rolled out alongside vaccination [S1].

Administrative - Nationwide training of health personnel preceded rollout [S1]. - Integration with U-WIN enables real-time tracking, cross-vaccine recognition (Gardasil-9, Cervarix, Cervavac entries updatable) [S1].

6. Recent Developments (last 12-18 months)

• 1 Feb 2024: Union Budget announced HPV vaccination push for 9–14 yrs girls under Nari Shakti [S5].
• 28 Feb 2026: PM Modi launched nationwide drive at Ajmer, Rajasthan [S2][S3].
• 13 Mar 2026: MoHFW notified compliance with 72nd PSC Report — research reforms + ethics oversight [S1].
• Mar 2026: Update on National HPV Vaccination Programme issued by MoHFW [S6].

7. Prelims Hooks

• HPV vaccine used in India's national programme: Gardasil-4 (quadrivalent — types 6, 11, 16, 18) [S2].
• Target age: 14 years (completed 14, not 15) [S2].
• Annual cohort size: ~1.15 crore girls [S2].
• Launch location: Ajmer, Rajasthan by PM on 28 Feb 2026 [S3].
• Schedule: Single dose (WHO-aligned) [S4].
• Digital platform for registration: U-WIN [S1].
• Consent regime: Voluntary with mandatory parental consent [S1].
• Indigenous HPV vaccine: CERVAVAC by Serum Institute of India [S5].
• Parliamentary Standing Committee report driving reforms: 72nd Report of DRSC on Health & Family Welfare [S1].
• Safety monitoring: AEFI mechanism [S1].
• India joins 160+ countries with HPV in national immunisation schedule [S4].
• Vaccine efficacy (vaccine-covered types): 93–100% [S4].

8. Mains Relevance

• GS-II: Issues relating to development & management of Social Sector/Services — Health; Government policies & interventions for vulnerable sections (women/adolescents).
• GS-III: Science & Technology — indigenisation, biotechnology, public health.
• Possible question stems: 1. "Single-dose HPV vaccination, integrated with the U-WIN platform, can decisively reduce India's cervical cancer burden. Discuss." 2. "Evaluate the role of Parliamentary Standing Committees in strengthening ethical oversight of clinical research in India, with reference to the 72nd Report on HPV vaccine trials." 3. "Indigenous vaccine development is central to India's health security. Examine in light of CERVAVAC and the HPV programme."

9. Related Topics to Study Next

• Universal Immunisation Programme (UIP) & Mission Indradhanush — parent framework HPV will plug into.
• U-WIN / Co-WIN digital platforms — digital public infrastructure for health.
• CERVAVAC & DBT-BIRAC — indigenous biotech ecosystem.
• WHO Cervical Cancer Elimination Strategy (90-70-90 by 2030) — global benchmark.
• AEFI surveillance & CDSCO/DCGI regulation — vaccine safety governance.
• Parliamentary Standing Committees (DRSCs) — accountability mechanism.
• National Health Mission (NHM) — delivery architecture.
• PATH HPV trials controversy (2009) — ethics precedent.

10. Common Errors / Trap Areas

• Gardasil-4 (quadrivalent) is the programme vaccine — NOT Gardasil-9 or Cervarix; CERVAVAC is indigenous but Gardasil-4 was operationalised for the 2026 rollout [S2].
• Target is 14-year-olds, not the 9–14 yr range announced in the 2024 Budget; rollout narrowed to a single age cohort [S2][S5].
• Schedule is single-dose, not two-dose — aligned with WHO 2022 revision [S2].
• Implementing ministry is MoHFW, not Ministry of Women & Child Development.
• Parliamentary report is the 72nd DRSC on Health, not the 81st (the 81st dealt with the original 2013 PATH inquiry — easy confusion) [S1].
• U-WIN, not Co-WIN, is the routine immunisation digital platform [S1].

11. Sources

• [S1] Measures taken to Strengthen HPV Vaccination Programme — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2239629 — (tier 1)
• [S2] PM Launches Nationwide HPV Vaccination Drive for 14-Year-Old Girls from Ajmer, Rajasthan — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2233906 — (tier 1)
• [S3] Prime Minister to Launch Nationwide HPV Vaccination Drive from Ajmer Tomorrow — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2233632 — (tier 1)
• [S4] Cervical Cancer Vaccination Campaign Launched — Key Takeaways (28 Feb 2026) — https://static.pib.gov.in/WriteReadData/specificdocs/documents/2026/feb/doc2026228807201.pdf — (tier 1)
• [S5] 'Nari Shakti' Takes Center Stage; Union FM Announces Vaccination to Prevent Cervical Cancer — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2001172 — (tier 1)
• [S6] Update on National HPV Vaccination Programme — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2241079 — (tier 1)